HALO - HALOZYME THERAPEUTICS, INC.
67.36
-2.660 -3.949%
Share volume: 1,840,308
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$70.02
-2.66
-0.04%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-07-2024 | 08-06-2024 | 10-31-2024 | 02-18-2025 | 05-06-2025 | 08-05-2025 | 11-03-2025 | 02-17-2026 | |
| Assets | |||||||||
| Total Assets | 1.842 B | 1.969 B | 2.118 B | 2.063 B | 2.197 B | 2.054 B | 2.221 B | 2.525 B | |
| Current Assets | 873.584 M | 987.797 M | 1.127 B | 1.085 B | 1.262 B | 1.123 B | 1.329 B | 825.207 M | |
| Inventories | 168.541 M | 159.312 M | 131.412 M | 141.860 M | 164.868 M | 181.505 M | 185.796 M | 176.475 M | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 298.824 M | 341.166 M | 511.988 M | 480.224 M | 571.594 M | 486.316 M | 282.298 M | 9.000 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 164.627 M | 187.864 M | 154.318 M | 115.850 M | 176.328 M | 61.861 M | 419.665 M | 133.820 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 78.071 M | 0.000 | 0.000 | 0.000 | 72.816 M | 0.000 | 0.000 | 0.000 | |
| Other Assets | 889.872 M | 981.656 M | 991.054 M | 978.137 M | 861.688 M | 931.226 M | 892.483 M | 1.700 B | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.842 B | 1.969 B | 2.118 B | 2.063 B | 2.197 B | 2.054 B | 2.221 B | 2.525 B | |
| Total liabilities | 1.664 B | 1.680 B | 1.665 B | 1.700 B | 1.714 B | 1.721 B | 1.717 B | 2.477 B | |
| Total current liabilities | 131.639 M | 133.360 M | 108.815 M | 139.100 M | 150.379 M | 134.282 M | 837.228 M | 177.092 M | |
| Accounts Payable | 13.325 M | 15.430 M | 12.398 M | 10.249 M | 20.074 M | 18.691 M | 15.360 M | 20.899 M | |
| Other liabilities | 31.201 M | 30.507 M | 40.406 M | 54.758 M | 56.436 M | 77.769 M | 71.799 M | 113.863 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 1.501 B | 1.503 B | 1.504 B | 1.506 B | 1.507 B | 1.509 B | 800.072 M | 2.143 B | |
| Other liabilities | 31.201 M | 30.507 M | 40.406 M | 54.758 M | 56.436 M | 77.769 M | 71.799 M | 113.863 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 177.808 M | 289.424 M | 452.703 M | 363.821 M | 482.270 M | 332.748 M | 503.915 M | 48.814 M | |
| Common stock | 11.921 M | 30.874 M | 62.013 M | 123.000 K | 7.719 M | 118.000 K | 24.027 M | 12.120 M | |
| Retained earnings | 167.373 M | 260.618 M | 397.629 M | 359.869 M | 477.964 M | 361.033 M | 502.146 M | 54.786 M |